secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001213900-25-016278
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar partners with TrialNet for Phase 2 study of rezpegaldesleukin in type 1 diabetes
--------------------------------------------------------------------------------

- TrialNet will conduct a Phase 2 randomized, placebo-controlled trial in ~70 adults and children with new onset stage 3 T1D.
- Nektar supplies rezpegaldesleukin, retains all program rights; TrialNet funds the study via NIH.
- Study aims to preserve beta-cell function using MMTT-measured C-peptide over 12 months; initiation targeted for 2025.
- Rezpegaldesleukin is also in Phase 2b trials for atopic dermatitis (REZOLVE-AD) and alopecia areata (REZOLVE-AA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025016278/0001213900-25-016278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025016278/ea0231907-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-016278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer